AGENT FOR EARLY CONTRAST DETECTION OF MALIGNANT PROLIFERATION CENTERS WITH FEEDING VESSELS, BOUNDARIES OF DIFFUSE INFILTRATION AND DETERMINATION OF STAGES OF THEIR DEVELOPMENT IN DYNAMICS Russian patent published in 2019 - IPC A61B5/55 A61K49/06 B82B3/00 C23C18/22 C23C22/05 

FIELD: medicine.

SUBSTANCE: group of inventions relates to experimental medicine, radiation diagnostics and pharmacology and can be used as an early contrast magnetic resonance tomographic (CMRT) detecting centres of malignant proliferation (CMP) and determining the stages of their development in vivo in dynamics, as well as method CMRT detecting CMP with feeding vessels and an expanding border of diffuse infiltration of malignant cells (MC) into normal tissues in experiment. Agent contains an aqueous sol of ferrimagnetic nanoparticles of citrateferrite of general formula (Fe₃O₄⁺)_m⋅(C₆H₇O₇^-)_n. First method involves synthesis of ferrimagnetic nanocrystals of non-stoichiometric magnetite, etching the obtained ferrimagnetic nanocrystals with 36 % hydrochloric acid to obtain an aqueous sol of nanocrystals of general formula from (1.05Fe²⁺O⋅1.85Fe³⁺₂O₃⋅0.1Fe³⁺OCl)_m to (1.15Fe²⁺O⋅1.75Fe³⁺₂O₃⋅0.1Fe³⁺OCl)_m and coating the obtained nanocrystals in aqueous ash with citrate anions. Second method involves intravenous administration to laboratory animals of an aqueous sol of compounds of general formula (Fe₃O₄⁺)m⋅(C₆H₇O₇^-)n for 10 min – 75 h before CMRT scanning of the examined region and primary intravenous introduction of Magnevist^® 3–9 minutes before CMRT scanning; carrying out CMRT scanning tissues in modes of producing T₁ B, T₂ B spin echo, T₂ B echo gradient and T*₂ B echo gradient; repeated intravenous introduction of Magnevist^® 3–5 minutes before CMRT scanning the analyzed region with visualizing the boundaries of diffuse infiltration of the MC into normal tissues and secondary intravenous introduction of an aqueous sol of compounds of general formula (Fe₃O₄⁺)m⋅(C₆H₇O₇^-)n 5–10 minutes before CMRT scanning the examined region with subsequent visualization of the contrast image of the diffuse infiltration of the MC into normal tissues; carrying out CMRT scanning tissues in modes of producing T₁ B, T₂ B spin echo, T₂ B echo gradient and T*₂ B echo gradient; inidentification CMP with feeding vessels and borders of diffuse infiltration of MC into normal tissues by changes of intensity of voxels in investigated area.

EFFECT: group of inventions provides selecting a combination of a negative and a positive contrast agent and optimal parameters CMRT scanning an animal's body for detecting CMP, early CMRT detection CMP and determining the developmental stages CMP in dynamics in experiment on immunocompetent animals with transplantable malignant tumors by synthesis of declared agent administered in different periods to CMRT scanning.

9 cl, 14 dwg, 2 tbl, 8 ex